29 results
8-K
EX-99.1
6ggg69o et
3 Nov 21
Agios Reports Business Highlights and Third Quarter 2021 Financial Results
7:27am
DEFM14A
mo4d7ci5155hb xn
11 Feb 21
Proxy related to merger
4:19pm
PREM14A
dzgjzehz
29 Jan 21
Preliminary proxy related to merger
4:22pm
DEFA14A
EX-2.1
bsne cpaxy0tm
21 Dec 20
Additional proxy soliciting materials
9:17pm
8-K
EX-2.1
lpf922ww9zg3qe
21 Dec 20
Entry into a Material Definitive Agreement
9:15pm
8-K
EX-99.1
s0hb n3421oyu2fmbr
30 Jul 20
Agios Reports Business Highlights and Second Quarter 2020 Financial Results
7:17am
8-K
EX-99.1
7fzbc
28 Oct 19
Agios Presents Data from Single Agent Dose-Escalation Arm of Phase 1 Study ofAG-270, a MAT2A Inhibitor, in Patients withMTAP-Deleted Tumors
7:20am
8-K
EX-99.2
oejsk12g9p
4 May 18
Results of Operations and Financial Condition
7:07am